Corcept Q2 Revenue Jumps 32% on Lifyorli Launch; CEO, CAO Adopt 10b5-1 Plans
CORT has more than doubled off its 52-week low of $28.66.
Summary
Corcept's Q2 revenue surged 32% to $256.1M on the Lifyorli launch, but six-month net income fell to $11.2M due to higher launch costs. The relacorilant NDA for Cushing's was resubmitted with a December 2026 PDUFA date. CEO and other insiders adopted 10b5-1 plans to sell up to 623,606 shares.
Key Events · Earnings and Guidance · CORT
-
Q2 Revenue Beats on Lifyorli Launch
Total revenue of $256.1M, up 32% YoY. Lifyorli contributed $47.6M in its first full quarter; Hypercortisolism Products grew 7% to $208.6M.
-
Profitability Squeezed by Launch Costs
Q2 net income of $43.0M ($0.36 diluted EPS) vs $35.1M a year ago, but six-month net income fell to $11.2M from $55.7M as SG&A nearly doubled to $302.3M for the Lifyorli launch.
-
Relacorilant NDA Resubmitted; December PDUFA
The NDA for relacorilant in Cushing's syndrome was resubmitted June 17, 2026, with a PDUFA target date of December 17, 2026 — a major binary catalyst.
-
CEO, CAO, Director Adopt 10b5-1 Plans
CEO Joseph Belanoff (up to 400,000 shares), CAO Joseph Lyon (120,000), and Director David Mahoney (103,606) adopted Rule 10b5-1 trading plans in May/June 2026.
Analysis · CORT · Life Sciences
Corcept's Q2 results show a strong commercial launch of oncology drug Lifyorli, which contributed $47.6M in its first quarter on the market, driving total revenue to $256.1M — a 32% increase year-over-year. The core Cushing's franchise also grew, with Hypercortisolism Products revenue up 7% to $208.6M. However, the six-month net income dropped sharply to $11.2M from $55.7M a year ago, as SG&A expenses nearly doubled to support the Lifyorli launch. The company holds a robust $544.6M in cash and securities, providing ample runway. On the regulatory front, the relacorilant NDA for Cushing's syndrome was resubmitted in June with a December 17, 2026 PDUFA date — a critical catalyst. The legal landscape remains challenging: the Federal Circuit denied rehearing of the Teva patent loss, cementing generic Korlym competition, and multiple litigations (securities class action, antitrust, qui tam) are ongoing. Separately, the CEO, CAO, and a director adopted 10b5-1 trading plans covering up to 623,606 shares, which could create overhang. The stock is trading near its 52-week high, reflecting optimism around Lifyorli and the relacorilant resubmission, but the insider selling plans and legal overhangs warrant attention.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CORT was trading at $112.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $28.66 to $97.63. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.